Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2024-2031

Report ID: 919282 | Published Date: Jan 2025 | No. of Page: 105 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Allogeneic
        1.2.3 Autologous
    1.3 Market by Application
        1.3.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Cancer Research Centers
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global CAR-T Therapy in Haematological Malignancy Market Perspective (2016-2027)
    2.2 CAR-T Therapy in Haematological Malignancy Growth Trends by Regions
        2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Share by Regions (2016-2021)
        2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2022-2027)
    2.3 CAR-T Therapy in Haematological Malignancy Industry Dynamic
        2.3.1 CAR-T Therapy in Haematological Malignancy Market Trends
        2.3.2 CAR-T Therapy in Haematological Malignancy Market Drivers
        2.3.3 CAR-T Therapy in Haematological Malignancy Market Challenges
        2.3.4 CAR-T Therapy in Haematological Malignancy Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue
        3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2016-2021)
        3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2016-2021)
    3.2 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
    3.4 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio
        3.4.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2020
    3.5 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served
    3.6 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
    3.7 Date of Enter into CAR-T Therapy in Haematological Malignancy Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 CAR-T Therapy in Haematological Malignancy Breakdown Data by Type
    4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2016-2021)
    4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027)

5 CAR-T Therapy in Haematological Malignancy Breakdown Data by Application
    5.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2016-2021)
    5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
    6.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Type
        6.2.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
        6.2.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
        6.2.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
    6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Application
        6.3.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
        6.3.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
        6.3.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
    6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Country
        6.4.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
        6.4.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
    7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type
        7.2.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
        7.2.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
        7.2.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
    7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application
        7.3.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
        7.3.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
        7.3.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
    7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country
        7.4.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
        7.4.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
    8.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type
        8.2.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
    8.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application
        8.3.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
    8.4 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region
        8.4.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
    9.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type
        9.2.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
        9.2.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
        9.2.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
    9.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application
        9.3.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
        9.3.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
        9.3.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
    9.4 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country
        9.4.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
        9.4.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
    10.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type
        10.2.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
    10.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application
        10.3.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
    10.4 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country
        10.4.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Celgene (Juno Therapeutics)
        11.1.1 Celgene (Juno Therapeutics) Company Details
        11.1.2 Celgene (Juno Therapeutics) Business Overview
        11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
        11.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.1.5 Celgene (Juno Therapeutics) Recent Development
    11.2 Novartis
        11.2.1 Novartis Company Details
        11.2.2 Novartis Business Overview
        11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
        11.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.2.5 Novartis Recent Development
    11.3 Gilead (Kite Pharma)
        11.3.1 Gilead (Kite Pharma) Company Details
        11.3.2 Gilead (Kite Pharma) Business Overview
        11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
        11.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.3.5 Gilead (Kite Pharma) Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Details
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
        11.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.4.5 Pfizer Recent Development
    11.5 CARsgen Therapeutics
        11.5.1 CARsgen Therapeutics Company Details
        11.5.2 CARsgen Therapeutics Business Overview
        11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
        11.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.5.5 CARsgen Therapeutics Recent Development
    11.6 Autolus Therapeutics
        11.6.1 Autolus Therapeutics Company Details
        11.6.2 Autolus Therapeutics Business Overview
        11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
        11.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.6.5 Autolus Therapeutics Recent Development
    11.7 Aurora BioPharma
        11.7.1 Aurora BioPharma Company Details
        11.7.2 Aurora BioPharma Business Overview
        11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction
        11.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.7.5 Aurora BioPharma Recent Development
    11.8 Sorrento Therapeutics
        11.8.1 Sorrento Therapeutics Company Details
        11.8.2 Sorrento Therapeutics Business Overview
        11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
        11.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.8.5 Sorrento Therapeutics Recent Development
    11.9 Mustang Bio
        11.9.1 Mustang Bio Company Details
        11.9.2 Mustang Bio Business Overview
        11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction
        11.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.9.5 Mustang Bio Recent Development
    11.10 Bluebird Bio
        11.10.1 Bluebird Bio Company Details
        11.10.2 Bluebird Bio Business Overview
        11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction
        11.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.10.5 Bluebird Bio Recent Development
    11.11 Collectis
        11.11.1 Collectis Company Details
        11.11.2 Collectis Business Overview
        11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction
        11.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.11.5 Collectis Recent Development
    11.12 Allogene Therapeutics
        11.12.1 Allogene Therapeutics Company Details
        11.12.2 Allogene Therapeutics Business Overview
        11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
        11.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.12.5 Allogene Therapeutics Recent Development
    11.13 Celyad
        11.13.1 Celyad Company Details
        11.13.2 Celyad Business Overview
        11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction
        11.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
        11.13.5 Celyad Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Allogeneic
    Table 3. Key Players of Autologous
    Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2016-2021)
    Table 8. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2022-2027)
    Table 10. CAR-T Therapy in Haematological Malignancy Market Trends
    Table 11. CAR-T Therapy in Haematological Malignancy Market Drivers
    Table 12. CAR-T Therapy in Haematological Malignancy Market Challenges
    Table 13. CAR-T Therapy in Haematological Malignancy Market Restraints
    Table 14. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2016-2021)
    Table 16. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020)
    Table 17. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
    Table 21. Date of Enter into CAR-T Therapy in Haematological Malignancy Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2016-2021)
    Table 25. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2016-2021)
    Table 29. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Celgene (Juno Therapeutics) Company Details
    Table 62. Celgene (Juno Therapeutics) Business Overview
    Table 63. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product
    Table 64. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 65. Celgene (Juno Therapeutics) Recent Development
    Table 66. Novartis Company Details
    Table 67. Novartis Business Overview
    Table 68. Novartis CAR-T Therapy in Haematological Malignancy Product
    Table 69. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 70. Novartis Recent Development
    Table 71. Gilead (Kite Pharma) Company Details
    Table 72. Gilead (Kite Pharma) Business Overview
    Table 73. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product
    Table 74. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 75. Gilead (Kite Pharma) Recent Development
    Table 76. Pfizer Company Details
    Table 77. Pfizer Business Overview
    Table 78. Pfizer CAR-T Therapy in Haematological Malignancy Product
    Table 79. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 80. Pfizer Recent Development
    Table 81. CARsgen Therapeutics Company Details
    Table 82. CARsgen Therapeutics Business Overview
    Table 83. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product
    Table 84. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 85. CARsgen Therapeutics Recent Development
    Table 86. Autolus Therapeutics Company Details
    Table 87. Autolus Therapeutics Business Overview
    Table 88. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product
    Table 89. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 90. Autolus Therapeutics Recent Development
    Table 91. Aurora BioPharma Company Details
    Table 92. Aurora BioPharma Business Overview
    Table 93. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product
    Table 94. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 95. Aurora BioPharma Recent Development
    Table 96. Sorrento Therapeutics Company Details
    Table 97. Sorrento Therapeutics Business Overview
    Table 98. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 99. Sorrento Therapeutics Recent Development
    Table 100. Mustang Bio Company Details
    Table 101. Mustang Bio Business Overview
    Table 102. Mustang Bio CAR-T Therapy in Haematological Malignancy Product
    Table 103. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 104. Mustang Bio Recent Development
    Table 105. Bluebird Bio Company Details
    Table 106. Bluebird Bio Business Overview
    Table 107. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product
    Table 108. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 109. Bluebird Bio Recent Development
    Table 110. Collectis Company Details
    Table 111. Collectis Business Overview
    Table 112. Collectis CAR-T Therapy in Haematological Malignancy Product
    Table 113. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 114. Collectis Recent Development
    Table 115. Allogene Therapeutics Company Details
    Table 116. Allogene Therapeutics Business Overview
    Table 117. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product
    Table 118. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 119. Allogene Therapeutics Recent Development
    Table 120. Celyad Company Details
    Table 121. Celyad Business Overview
    Table 122. Celyad CAR-T Therapy in Haematological Malignancy Product
    Table 123. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
    Table 124. Celyad Recent Development
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2020 VS 2027
    Figure 2. Allogeneic Features
    Figure 3. Autologous Features
    Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2027
    Figure 5. Hospitals Case Studies
    Figure 6. Cancer Research Centers Case Studies
    Figure 7. Others Case Studies
    Figure 8. CAR-T Therapy in Haematological Malignancy Report Years Considered
    Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2020 VS 2027
    Figure 12. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2022-2027)
    Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2020
    Figure 14. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2020
    Figure 16. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2016-2021)
    Figure 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2022-2027)
    Figure 18. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
    Figure 20. North America CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
    Figure 21. North America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
    Figure 22. United States CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
    Figure 26. Europe CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
    Figure 27. Europe CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
    Figure 28. Germany CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2016-2027)
    Figure 38. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
    Figure 46. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
    Figure 47. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
    Figure 48. Mexico CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
    Figure 54. Turkey CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 58. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 59. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 60. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 61. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 62. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 63. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 64. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 65. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 66. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 67. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 68. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 69. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Frequently Asked Questions
CAR-T Therapy in Haematological Malignancy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
CAR-T Therapy in Haematological Malignancy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
CAR-T Therapy in Haematological Malignancy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports